THREE-YEAR FOLLOW-UP OF A PILOT STUDY OF RANIBIZUMAB COMBINED WITH PROTON BEAM IRRADIATION AS TREATMENT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION-Reference-Cited by-同舟云学术

THREE-YEAR FOLLOW-UP OF A PILOT STUDY OF RANIBIZUMAB COMBINED WITH PROTON BEAM IRRADIATION AS TREATMENT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION

Published:2012-05 Issue:5 Volume:32 Page:956-966
ISSN:0275-004X
Container-title:Retina
language:en
Short-container-title:

Author:

Park Susanna S.,Daftari Inder,Phillips Theodore,Morse Lawrence S.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Ophthalmology,General Medicine

Reference23 articles.

1. . Prevalence of age-related macular degeneration in the United States.;Friedman;Arch Ophthalmol,2004

2. . Forecasting age-related macular degeneration through the year 2050.;Rein;Arch Ophthalmol,2009

4. . Ranibizumab versus verteporfin for neovascular age-related macular degeneration.;Brown;N Engl J Med,2006

5. . Ranibizumab for neovascular age-related macular degeneration.;Rosenfeld;N Engl J Med,2006

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dosimetry modeling of focused kV x‐ray radiotherapy for wet age‐related macular degeneration;Medical Physics;2020-08-12

2. Phase I/II randomized study of proton beam with anti-VEGF for exudative age-related macular degeneration: long-term results;Eye;2020-02-13

3. Radiation Therapy for Benign Disease;Hematology/Oncology Clinics of North America;2020-02

4. Age-Related Macular Degeneration;Current Practices in Ophthalmology;2018

5. Phase I/II Randomized Study of Proton Beam with Anti–Vascular Endothelial Growth Factor for Exudative Age-Related Macular Degeneration;Ophthalmology Retina;2017-05